Key Drivers
- Negative Equity
- Cash Burn
- Debt Dependence
AIAI Summary
NBTX is a high-risk clinical-optionality trade, not a de-risked oncology investment: its promising 24-patient NSCLC signal must be replicated in larger controlled studies while heavy cash burn, negative equity, and a ~40x-sales valuation make dilution or financing pressure likely; investors should wait for stronger clinical validation or treat support near $33–34 as a tightly risk-managed entry point.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Negative Equity
- •Cash Burn
- •Debt Dependence
NBTX's strong revenue base is overshadowed by recurring losses, heavy cash burn, negative equity, debt reliance, and a demanding valuation, warranting high caution.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Oversold momentum
- •Critical support
NBTX remains bearish below its last-month average, with $33.00–$34.00 support critical; a break lower signals further downside, while reclaiming $37.00–$38.20 could support a rebound.
Roughly 24% decline over the past month
Sentiment & News
Key News Insights:
- •Favorable Safety
- •Strong Local Control
- •Enrollment Continues
Nanobiotix reported encouraging Phase 1 JNJ-1900 lung cancer data with favorable safety and 79% one-year locoregional control, supporting further enrollment.
The results could bolster investor confidence in Nanobiotix's clinical development outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings